[ET Net News Agency, 9 April 2021] Credit Suisse raised its target price for China
Traditional Chinese Medicine (CTCM) (00570) to HK$5.1 from HK$4.3 and downgraded its
rating to "neutral" from "outperform".
The research house said the deregulation of TCM granules is expected to increase
competition, while also setting up higher standards of manufacturers. It believes
CTCM is well prepared for the new opportunities and challenges post the market
liberalisation, as the company has obtained necessary qualification for 17 production
enterprises within the group, expanded capacity to 22 provinces in China, accelerated the
construction of Good Agriculture and Collection Practices for Medicinal Plants (GACP)
bases to improve quality control of TCM sources, promoted the establishment
of provincial standards for concentrated TCM granules to reduce future risks and
established strong relationship with a large number of medical institutions. (RC)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
00570 TRAD CHI MED
Nominal 
4.320 -0.010 (-0.231%) Research Report
09/04/2021 17:09
{I-bank focus}CS raises Trad Chi Med (00570) to HK$5.1
| Remark: | Real time quote last updated: 25/04/2024 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |